Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2017 08:00 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. Initiates Pivotal Bioequivalence Fed Study for Reformulated SequestOx™

NORTHVALE, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced today that it has initiated pharmacokinetic testing of its...
February 09, 2017 16:34 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. Reports Results for Third Quarter of Fiscal Year 2017

NORTHVALE, N.J., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced results for the quarter ended December 31, 2016, the third quarter...
February 07, 2017 08:00 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2017 Financial Results on February 13, 2017

NORTHVALE, N.J., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
January 23, 2017 08:18 ET | Source: Elite Pharmaceuticals, Inc.

Elite Reports On SequestOx™ FDA End-of-Review Meeting

NORTHVALE, N.J., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported the Company received official minutes from its December 21, 2016...
January 17, 2017 08:00 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study for a Generic OxyContin®

NORTHVALE, N.J, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from a pivotal bioequivalence fed study...
December 22, 2016 12:31 ET | Source: Elite Pharmaceuticals, Inc.

Elite Provides Update on SequestOx™ New Drug Application

NORTHVALE, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced the Company met with the U.S. Food and Drug Administration (the...
December 12, 2016 08:00 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals Files ANDA for Hydrocodone and Acetaminophen Combo

NORTHVALE, N.J., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that it has filed an Abbreviated New Drug Application (ANDA)...
November 09, 2016 16:37 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2017 and Provides Conference Call Information

NORTHVALE, N.J., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
November 07, 2016 12:51 ET | Source: Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 2nd Quarter 2017 Financial Results on November 10, 2016

NORTHVALE, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
August 29, 2016 09:01 ET | Source: Elite Pharmaceuticals, Inc.; SunGen Pharma, LLC

Elite Announces Development and License Agreement with SunGen Pharma LLC

NORTHVALE, N.J., Aug. 29, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...